Malignant endocrine neoplasm

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

This phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…

This phase 2 trial tests the drug cabozantinib in 35 people with high-grade neuroendocrine tumors that have worsened after at least one prior treatment. These are rare, fast-growing cancers with limited options. The study aims to see if cabozantinib can shrink tumors or slow thei…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …

This early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…

This early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…

This study tests different combinations of chemotherapy drugs, along with surgery, for children and young adults with two types of liver cancer: hepatoblastoma and hepatocellular carcinoma. The goal is to see which combinations work best to stop tumor growth and improve survival.…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…

This pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one …

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This study tests the drug vemurafenib in 24 people with advanced papillary thyroid cancer that has a BRAF gene mutation. The drug aims to block this mutation to shrink tumors before surgery. Researchers will measure changes in tumor size and biomarkers in blood and tissue over 56…

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …

This phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…

This phase 3 trial tests whether adding pembrolizumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer. About 672 participants will receive either the drug combo or a pla…

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have n…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …

This phase 3 trial tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without the disease worsening. Participants first receive standard induction chemo-immunotherapy, then those with stab…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This Phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer, a rare and fast-growing cancer with no standard cure. Participants receive the drug every three weeks to see if tumors shrink or stop growing. The study …

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…

This trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This phase 2 trial tests whether adding two drugs (durvalumab and ceralasertib) after standard chemo-immunotherapy can help control extensive-stage small cell lung cancer. About 30 people who have not had prior treatment will receive the combination. The main goal is to see how l…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinatio…

This trial compares two treatment approaches for pancreatic neuroendocrine tumors that have spread or cannot be removed surgically. One group receives lutetium Lu 177 dotatate, a radioactive drug that targets tumor cells, while the other receives a combination of chemotherapy dru…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This phase II trial is testing whether a combination of three treatments—QL1706 (an immunotherapy), lenvatinib (a targeted therapy), and GEMOX (two chemotherapy drugs)—can help people with bile duct or gallbladder cancer that cannot be removed by surgery. The study will enroll ab…

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 2 trial is testing tarlatamab, an experimental drug given by IV, in 252 adults with small cell lung cancer that has worsened after platinum-based chemotherapy. The main goal is to see if the drug can shrink tumors (partial or complete response). Researchers will also m…

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…

This phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive …

This trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…

This study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has not responded to prior treatment. The goal is to confirm the drug's safety and effectiveness. Participants take the tablet once daily in 28-…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This phase 3 trial tests whether the immunotherapy drug nivolumab can prevent liver cancer from coming back in people who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. The…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…

This Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This phase 2 study tests a drug called tarlatamab in 222 people with relapsed or refractory small cell lung cancer who have already tried at least two prior treatments. The goal is to see if tarlatamab can shrink tumors and how safe it is. Participants receive the drug through an…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tested adding the immunotherapy drug durvalumab (with or without another drug, tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either chemo alone or ch…

This phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. Researchers will also monitor side effects and how long any response l…

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy.…

This Phase 3 trial tests an oral drug called tinengotinib against standard treatments chosen by the doctor for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic alteration (FGFR) and has stopped responding to chemotherapy and an FGFR inhibitor…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…

This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patien…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This phase 2 trial tests the experimental drug MGC018 in 9 people with relapsed or refractory extensive-stage small-cell lung cancer. The main goal is to see if the drug can shrink tumors in at least 25% of patients. Participants receive MGC018 by IV every 28 days until the cance…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…

This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …

This study follows 254 adults with extensive-stage small cell lung cancer who are receiving durvalumab (Imfinzi) along with standard chemotherapy. The goal is to see how long patients stay on treatment and how well it works in real-world settings. The approach uses the immune sys…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…

This study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…

This early-phase trial tests a combination of three drugs—tarlatamab, YL201, and durvalumab—in 29 adults with extensive stage small cell lung cancer that has progressed after prior treatment. The main goal is to check safety and side effects, while also measuring how well the tum…

This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers wil…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests whether using I-124 PET/CT scans can help doctors decide which thyroid cancer patients truly need radioiodine ablation therapy. About 340 adults with newly diagnosed differentiated thyroid cancer will be assigned to either standard care or I-124-guided care. The …

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This study looks at whether low-risk thyroid cancer patients need radioactive iodine treatment after having their thyroid removed. About 504 participants are randomly assigned to receive either a standard dose of radio-iodine or no radio-iodine at all. The goal is to see if skipp…

This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…

This phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior…

This study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This phase 3 study tests whether tarlatamab, an experimental drug, can delay cancer progression or improve survival in people with limited-stage small-cell lung cancer who have finished chemoradiation without their cancer getting worse. About 404 participants will receive either …

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…

This phase II trial tests whether the immune-boosting drug durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from progressing after standard chemoradiotherapy. About 100 participants who have stable or improved disease after initial t…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) can help people with advanced large-cell neuroendocrine lung cancer live longer. About 67 participants who have not had prior systemic treatment wil…

This study tests whether adding the immunotherapy drug atezolizumab after standard chemo-radiotherapy helps people with limited-stage small-cell lung cancer live longer. About 212 participants will receive either atezolizumab or no additional treatment after chemo-radiation. The …

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…

This study tests whether the drug selpercatinib works better than current standard treatments for people with a specific type of advanced thyroid cancer (medullary thyroid cancer with a RET gene mutation). About 291 adults (and some teens) whose cancer has spread or can't be remo…

This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug docetaxel can shrink or control advanced thyroid and salivary gland cancers that are not responding to standard treatments. About 46 participants will receiv…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This early-stage trial is for people with stage IV non-small cell lung cancer. It tests whether giving targeted radiation before or at the same time as two immunotherapy drugs (nivolumab and ipilimumab) is safe. The goal is to find the best radiation dose for different tumor loca…

This study looks at whether removing only the thyroid gland works as well as also removing nearby lymph nodes in people with low-risk thyroid cancer. About 352 patients with small to medium-sized tumors will be randomly assigned to one of the two surgeries. The goal is to see if …

This study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 we…

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This study tests a minimally invasive procedure called radiofrequency to treat thyroid cancer that has spread to lymph nodes in the neck. It involves 14 adults who have already had surgery and radioactive iodine therapy. The goal is to see if the heat-based treatment can shrink o…

This phase 2 study tests a drug called ifinatamab deruxtecan (I-DXd) in 187 people with extensive-stage small cell lung cancer that has already been treated with chemotherapy. The drug is designed to target and kill cancer cells. Researchers are checking how many patients' tumors…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…

This study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…

This phase 2 trial tests two drugs, pembrolizumab and lenvatinib, in 30 adults with advanced adrenal cortical carcinoma that has worsened after standard chemotherapy. The goal is to see if the combination can shrink or slow the cancer. Participants receive the drugs intravenously…

This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…

This phase II trial is testing a combination of chemotherapy (carboplatin and etoposide) with immunotherapy (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib, in 20 people with advanced high-grade neuroendocrine tumors who have not had prior chemo…

This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …

This trial tests a device called HistoSonics that uses focused ultrasound (sound waves) to mechanically destroy liver tumors without heat or needles. It includes 24 adults with liver cancer or tumors that spread to the liver. The main goals are to see if the device can fully cove…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study tests whether simvastatin, a drug typically used for cholesterol, can reduce the risk of liver complications in veterans with compensated cirrhosis (scarred but symptom-free liver). About 142 participants will take either simvastatin or a placebo nightly for several ye…

This phase 3 study compares tarlatamab, an experimental drug, to standard treatments in about 500 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease…

This phase 3 trial is testing whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab helps people with advanced liver cancer that cannot be surgically removed. About 687 participants will receive either the three-drug combo or the two-drug combo pl…

This phase 3 trial tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 participants who have already completed initial chemotherapy plus durvalumab will be randomly assigned to one of …

This study looks at how well a treatment called 90Y radioembolization works for people with early-stage liver cancer. Researchers will track 200 patients in Korea to see how the tumors respond, how long patients live, and any side effects. The goal is to gather real-world data to…

This phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This phase 3 trial tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help prevent cancer progression in people with limited-stage small cell lung cancer who have completed chemoradiation. About 730 participants will receive either the drug combin…

This trial tests a device called HistoSonics that uses focused ultrasound waves to mechanically destroy liver tumors without heat, needles, or incisions. About 47 adults with liver cancer or tumors that spread to the liver will receive this treatment. The main goals are to see if…

This study tests an immunotherapy called AlloStim against standard treatments (sorafenib, lenvatinib, or chemotherapy) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. Participants are randomly assigned to receive either AlloS…

This early-phase trial tests a new experimental treatment called GAP T cells in children and young adults with liver cancer that has come back or not responded to standard therapy. The cells are made from the patient's own immune T cells, which are genetically modified to recogni…

This study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as the standard higher dose (140 mg) in people with progressive, metastatic medullary thyroid cancer. The goal is to see if the lower dose can control cancer growth for a similar length of time w…

This study compares MRI scans to standard CT scans for staging thymoma, a rare chest tumor. Researchers want to see if MRI can detect tumor spread just as well or better, without using radiation. Forty adults with newly diagnosed or recurrent thymoma will undergo both scans befor…

Researchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…

Researchers are testing a technique called Raman spectroscopy to see if it can accurately identify thyroid cancer in tissue samples. The study involves patients who are already having a routine thyroid biopsy for suspected cancer. After the biopsy, the removed tissue is examined …

This study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…

This study is testing a new way to analyze thyroid nodules that look suspicious but not clearly cancerous. Researchers are checking if a set of microRNA molecules can better predict which nodules are actually cancer. The goal is to help patients avoid unnecessary surgery. The stu…

Researchers are testing a blood test panel called Glycotest HCC to see if it detects early-stage liver cancer better than the standard alpha-fetoprotein (AFP) test. The study includes 766 people with cirrhosis, some of whom have early liver cancer and some who do not. Participant…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…

This study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

Researchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…

This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

Researchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…

This early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…

This study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…

This study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This trial compares two ways to control pain after open liver surgery: an epidural pump that delivers pain medicine near the spine, versus a standard IV pump. About 230 adults having elective open liver resection will be randomly assigned to one method. The goal is to see which a…

This study trains home-care nurses to deliver a short, meaning-centered psychotherapy to cancer patients who are homebound. The goal is to see if this approach can reduce psychological distress and improve quality of life. The trial involves 81 participants and focuses on trainin…

This study tests whether giving haloperidol alone or with chlorpromazine can safely calm severe agitation and confusion (delirium) in 70 advanced cancer patients in a palliative care unit. The main goal is to see if the drugs improve sedation scores within 24 hours. It is a phase…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…

This study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…

Depression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…

Researchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…

This study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…

This study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…

This trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…

This study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…

This study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …

This pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…

This study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…

This study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…

This study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…

This study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…

Researchers at the University of Aarhus are studying whether people with a single thyroid cancer smaller than 2 cm can safely delay surgery and instead have the tumor monitored with ultrasound for five years. The study enrolls 90 adults aged 30 and older whose biopsy shows cancer…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study follows children and adults with medullary thyroid cancer (MTC), often linked to a genetic condition called MEN2. Researchers will track how the cancer grows and affects health over time using regular check-ups, blood tests, and imaging. No treatment is given, but part…

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…

This study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…

Researchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This trial studies whether small differences in genes affect how patients with small cell lung cancer respond to the chemotherapy drug etoposide and how severe its side effects are. Researchers will analyze DNA from 600 patients who take etoposide capsules, comparing two versions…

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This study explores whether a remote, direct-to-patient approach can improve how people with small cell lung cancer (SCLC) are reached and engaged in clinical research. It involves collecting biospecimens and surveying patients about their preferences and needs regarding new ther…

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…

This study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut b…

This study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compar…

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…

This study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study observes how doctors in Russia treat inoperable lung cancer (NSCLC and SCLC) using chemoradiotherapy. Researchers will collect data from 2000 patients across 50 cancer centers to understand real-world practices and short-term outcomes. No new treatments are given; the …

This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…

This study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…

This small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…

This study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …

This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways …

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…

This pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…

This study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary l…

This study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool…

This study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study reviews medical records of 300 people diagnosed with choledochal cysts (bile duct cysts) between 2000 and 2020 in Western hospitals. The goal is to find out how often these cysts lead to bile duct cancer and what factors increase that risk. By analyzing symptoms, treat…

This study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…

This study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to …

This study examines why some papillary thyroid cancers respond well to radioactive iodine-131 therapy while others do not. Researchers will compare tissue samples and PET scans from 60 patients who have already had treatment, focusing on a protein called Trop2. The goal is to und…

This study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…

This study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…

This study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…

This study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…

This study follows 200 adults with low-risk papillary thyroid cancer to see how many choose active surveillance (close monitoring) instead of surgery, and why. Researchers also track decision regret and quality of life over time. The goal is to understand if offering monitoring a…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study is collecting blood and tissue samples from 360 people with early-stage liver cancer who have had surgery to remove their tumors. Researchers want to find biological markers that could predict if the cancer will come back. The goal is to better understand the immune sy…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…

This study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…

This study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm…

This study aimed to see if thyroid surgery changes the thickness of the carotid artery, which is a sign of heart disease risk. It planned to measure artery thickness before and after surgery in adults with various thyroid conditions. However, the study was withdrawn before enroll…